2022
Body mass index from the RE-LY trial: further evidence of the obesity paradox
Jacobs M, Ezekowitz M, Nagarakanti R, Eikelboom J, Khan O, Reiss J, Liu H, McAndrew T, Francese D, Arce J, Brueckmann M, Connolly S, Yusuf S. Body mass index from the RE-LY trial: further evidence of the obesity paradox. European Heart Journal 2022, 43: ehac544.629. DOI: 10.1093/eurheartj/ehac544.629.Peer-Reviewed Original ResearchBody mass indexDirect oral anticoagulantsRE-LY trialObesity paradoxMajor bleedingIntracranial hemorrhageSystemic embolismIschemic strokeDrug assignmentMass indexResults Body mass indexHigher body mass indexWorld Health Organization criteriaCox proportional hazards modelIntracranial hemorrhage rateIschemic stroke rateRates of diabetesProportional hazards modelContinuous variablesLower ratesPrior strokeOral anticoagulantsRE-LYBaseline characteristicsCreatinine clearance
2016
Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials
Giustino G, Mehran R, Bansilal S, Feit F, Lincoff M, Deliargyris EN, Kirtane AJ, Généreux P, Redfors B, Prats J, Bernstein D, Brener SJ, Skerjanec S, Lansky AJ, Francese DP, Dangas GD, Stone GW. Safety and Efficacy of Bivalirudin in Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: From the REPLACE-2, ACUITY and HORIZONS-AMI Trials. The American Journal Of Cardiology 2016, 118: 6-16. PMID: 27181566, DOI: 10.1016/j.amjcard.2016.04.005.Peer-Reviewed Original ResearchConceptsGlycoprotein IIb/IIIa inhibitorsPercutaneous coronary interventionMajor adverse cardiac eventsEfficacy of bivalirudinAdverse cardiac eventsDiabetes mellitusMajor bleedingCoronary interventionBivalirudin treatmentCause mortalityCardiac eventsNon-coronary artery bypass graft-related major bleedingPrimary efficacy end pointPrimary safety end pointUrgent Intervention Triage StrategyAcute Myocardial Infarction trialIIb/IIIa inhibitorsEnd pointHORIZONS-AMI trialPCI Linking AngiomaxComposite of deathEfficacy end pointMyocardial Infarction trialSafety end pointPatient-level dataImpact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study
Giustino G, Kirtane AJ, Baber U, Généreux P, Witzenbichler B, Neumann FJ, Weisz G, Maehara A, Rinaldi MJ, Metzger C, Henry TD, Cox DA, Duffy PL, Mazzaferri EL, Brodie BR, Stuckey TD, Gurbel PA, Dangas GD, Francese DP, Ozan O, Mehran R, Stone GW. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. The American Journal Of Cardiology 2016, 117: 1877-1883. PMID: 27131611, DOI: 10.1016/j.amjcard.2016.03.034.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnemiaAspirinBlood PlateletsClopidogrelCoronary Artery DiseaseDrug Therapy, CombinationDrug-Eluting StentsEuropeFemaleHemorrhageHumansIncidenceMaleMiddle AgedMyocardial IschemiaPercutaneous Coronary InterventionPlatelet AggregationPlatelet Aggregation InhibitorsProspective StudiesRegistriesRisk AssessmentRisk FactorsSurvival RateTiclopidineUnited StatesConceptsHigh platelet reactivityDrug-Eluting Stents studyMajor adverse cardiac eventsAdverse cardiac eventsDual antiplatelet therapyPlatelet reactivityAntiplatelet therapyMajor bleedingCause mortalityCardiac eventsMultivariate adjustmentStent studiesWorld Health Organization criteriaImpact of anemiaPresence of anemiaPercutaneous coronary interventionDrug-eluting stentsIschemic riskBleeding riskClinical confoundersCoronary interventionAnemic patientsClinical outcomesHemoglobin levelsStudy cohort
2015
The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial.
Madhavan MV, Généreux P, Palmerini T, Caixeta A, Xu K, McAndrew TC, Francese DP, Kirtane AJ, Mehran R, Stone GW. The association between the extent of coronary artery disease and major bleeding events after percutaneous coronary intervention: from the ACUITY trial. Journal Of Invasive Cardiology 2015, 27: 203-11. PMID: 25840404.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedCoronary AngiographyCoronary Artery BypassCoronary Artery DiseaseFemaleHumansMaleMiddle AgedMulticenter Studies as TopicMultivariate AnalysisPercutaneous Coronary InterventionPostoperative HemorrhageProportional Hazards ModelsProspective StudiesRandomized Controlled Trials as TopicRisk FactorsConceptsNon-ST segment elevation acute coronary syndromesPercutaneous coronary interventionCoronary artery diseaseExtent of CADMajor bleeding ratesSYNTAX scoreACUITY trialMajor bleedingCoronary interventionArtery diseaseBleeding rateSegment elevation acute coronary syndromesSeverity of CADElevation acute coronary syndromeSevere coronary artery diseaseAdverse ischemic eventsMajor bleeding eventsAcute coronary syndromeCommon risk factorsRecurrent adverse eventsBleeding eventsPCI cohortSS tertilesCoronary syndromeHemorrhagic events